Association of plasma ceramide with decline in kidney function in patients with type 2 diabetes
Open Access
- 3 May 2024
- journal article
- research article
- Published by Elsevier in Journal of Lipid Research
- Vol. 65 (6) , 100552
Abstract
No abstract availableKeywords
Funding Information
- National Medical Research Council
- Alexandra Health Pte Ltd
This publication has 49 references indexed in Scilit:
- Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart diseaseDiabetes & Metabolism, 2021
- Relation Between Plasma Ceramides and Cardiovascular Death in Chronic Heart Failure: A Subset Analysis of the GISSI-HF TrialESC Heart Failure, 2020
- Could Ceramides Become the New Cholesterol?Cell Metabolism, 2018
- Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetesKidney International, 2017
- Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney DiseaseKidney International Reports, 2017
- Very long chain ceramides interfere with C16-ceramide-induced channel formation: A plausible mechanism for regulating the initiation of intrinsic apoptosisBiochimica et Biophysica Acta (BBA) - Biomembranes, 2015
- CerS2 Haploinsufficiency Inhibits β-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin ResistanceCell Metabolism, 2014
- Obesity is a determinant of arterial stiffness independent of traditional risk factors in Asians with young-onset type 2 diabetesAtherosclerosis, 2014
- Ceramide synthases as potential targets for therapeutic intervention in human diseasesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2014
- Mammalian ceramide synthasesIUBMB Life, 2010